PD-1/PD-L1 inhibitors monotherapy have been approved by the Food and Drug Administration (FDA) and the National Medical Products Administration (NMPA) of China for the second or later-line treatment of patients with driver-negative advanced non-small cell lung cancer. This evidence concerns the gene CD274 and non-small cell lung carcinoma.